<DOC>
	<DOCNO>NCT02748837</DOCNO>
	<brief_summary>This open label , multicenter Phase 1 study consist dose escalation determine maximum tolerate dose ( MTD ) cohort expansion obtain preliminary evaluation anti-tumor activity . ERY974 intravenously inject patient Glypican 3 positive advance solid tumor unacceptable toxicity disease progression .</brief_summary>
	<brief_title>A Study ERY974 Patient With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female patient Glypican 3 positive advance solid tumor amenable standard therapy standard therapy available indicate Measurable tumor Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver , renal function Adequate coagulation status Patients single brain metastasis ( &gt; 1 cm ) Patients acute chronic infection Major surgery within 28 day Pregnant lactate woman Patients interstitial pneumonitis Patients require regular ascites/pleural effusion drainage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>